
|Videos|August 19, 2021
Dr. Danila on how he chooses among androgen receptor inhibitors in castration-resistant prostate cancer
Author(s)Urology Times staff
Daniel C. Danila, MD, discusses choosing among the androgen receptor inhibitors darolutamide, enzalutamide, and apalutamide when treating patients with castration-resistant prostate cancer.
Advertisement
Daniel C. Danila, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses choosing among the androgen receptor inhibitors darolutamide (Nubeqa), enzalutamide (Xtandi), and apalutamide (Erleada) when treating patients with castration-resistant prostate cancer.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves ProVee System for benign prostatic hyperplasia
4
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
5


















